eHealth (EHTH) Tops Q3 EPS by 22c, Offers FY Guidance

eHealth (NASDAQ: EHTH) reported Q3 EPS of ($0.36), $0.22 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $94.3 million versus the consensus estimate of $87.35 million.

GUIDANCE:

eHealth sees FY2020 EPS of $3.83-$4.32, versus the consensus of $4.22. eHealth sees FY2020 revenue of $630-670 million, versus the consensus of $653.7 million.

• Total revenue is expected to be in the range of $630.0 million to $670.0 million. Revenue from the Medicare segment is expected to be in the range of $583.0 million to $619.0 million. Revenue from the Individual, Family and Small Business segment is expected to be in the range of $47.0 million to $51.0 million.
• GAAP net income is expected to be in the range of $79.0 million to $94.0 million.
• Adjusted EBITDA(a) is expected to be in the range of $140.0 million to $155.0 million.
• Medicare segment profit(b) is expected to be in the range of $176.0 million to $193.0 million. Individual, Family and Small Business segment profit is expected to be in the range of $17.0 million to $18.0 million.
• Corporate(c) shared service expenses, excluding stock-based compensation and depreciation and amortization, is expected to be in the range of $53.0 million to $56.0 million.
• Cash used in operations is expected to be in the range of $85.0 million to $95.0 million, and cash used for capital expenditures is expected to be in the range of $23.0 million to $25.0 million.
• GAAP net income per diluted share is expected to be in the range of $2.91 to $3.47.
• Non-GAAP net income per diluted share(d) is expected to be in the range of $3.83 to $4.32.

For earnings history and earnings-related data on eHealth (EHTH) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised
• Amylyx ALS drug shows no serious adverse events in Phase 1 trial